Figure 7
p38MAPK and GSK3 β protein expression by Western blots in the WSU-WM model. A. Expression in xenograft tumors taken from SCID mice following treatment with 1, 2 or 3 injections with rituximab, 2-CdA or the two agents (combo). 50 μg total tumor tissue lysates were subjected to Western blot for detection of phospho-p38MAPK, phospho-GSK3β using GAPDH as a loading control; B. Effect of chemical inhibition of p38MAPK on GSK3β expression in vitro. WSU-WM cells in culture were exposed to 2-CdA (50nM), RTX (100 μg), or combo (2-CdA + RTX). 48 h later, DMSO (vehicle) or p-38MAPK inhibitor SB203580 (30 μM) were added and cultures were maintained for an additional 48 h. At the end of incubation, lysates were collected and subjected to immunoblotting using GAPDH as loading control.